Issue of Alcohol Dose dumping [Regulatives / Guidelines]

posted by Chiku – India, 2012-01-11 09:10 (5283 d 04:36 ago) – Posting: # 7896
Views: 11,948

Dear all,

Good morning!

We are developing XR generic formulation (market US). Our formulation is bioequivalent as well as F2 value is matching in all the required dissolution mediums.

The problem is we are failing in alcohol dose dumping study in 0.1 N HCl. what is the way out in this situation? wether regulatory (US FDA) will accept the dossier. Any justification can be provided?

Further i read the following thread
I get to understand EU's thinking but still confused about FDA's thinking. product developed is not opioid in this case.

In our case F2 value is not matching few other statistical methods for dissolution calculation shows similarity. based on this can i give justification? or else reformulation is the only way out? We used eudragit and Innovator has used HPMC polymer.


Thank you in anticipation!

Regards

Chiku:)


Copypasted last two paragraphs from a follow-up post. You can edit your own posts for 24 hours; no need to post a new one. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
270 visitors (1 registered, 269 guests [including 14 identified bots]).
Forum time: 14:46 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5